Background: Antimicrobial exposure is associated with increased risk of Clostridium difficile infection (CDI), but the impact of prescribing interventions on CDI and other outcomes is less clear.
Introduction
Clostridium difficile is the leading cause of healthcare-associated infective diarrhoea. C. difficile infection (CDI) is potentially life threatening and risk of infection is increased by recent exposure to antimicrobials. 1 In comparison with other antimicrobials, exposure to cephalosporins and clindamycin has been associated with higher risk of CDI in hospitals. 2 At the population level, fluoroquinolone use has been associated with infection by fluoroquinolone-resistant epidemic strains and, in the UK, restriction of fluoroquinolones has been associated with a reduction in total CDI and in fluoroquinolone-resistant clones from 67% to 3% of all CDI. 3 The direct impact of antimicrobial prescribing interventions on CDI rates is less clearly demonstrated. A recent systematic review of interventions to improve antibiotic prescribing for hospital inpatients 4 found no randomized controlled trials and 26 interrupted time series (ITS) studies that provided reliable data about the impact of interventions on both prescribing and microbial (CDI or resistant Gram-positive and -negative bacteria) outcomes. Nine planned prescribing interventions (i.e. not in response to an outbreak) reported heterogeneous effects on CDI rates. [5] [6] [7] [8] [9] [10] [11] [12] [13] In 2008, antimicrobial policy changes across Ninewells Hospital, Dundee were initiated, following national guidance on restriction of antimicrobials associated with a high risk of CDI [highrisk antimicrobials (HRA)], designed to reduce prescribing of these agents. The aims of this study were to evaluate the impact of these policy changes on HRA prescribing rates, CDI and mortality in Medical and Surgical Wards in Ninewells Hospital, using segmented regression analysis of ITS data, then to compare these findings with similar studies from the above systematic review to understand better the variation in the impact of HRA prescribing interventions on CDI.
Methods

Setting and population
Ninewells Hospital is an 855 bed university hospital in the NHS region of Tayside, which had endemic CDI at a rate of 1.5 cases per 1000 acute occupied bed days (OBD) in 2008. The study period was October 2006 to September 2010. We evaluated intervention effects in Medical and Surgical wards and included all patients aged 18 years admitted through the Acute Medical Unit or one of six general Surgical wards. Further details of the setting, population and intervention are available in Table S1 (available as Supplementary data at JAC Online), reported according to the ORION statement recommendations. 14 
Intervention
Antimicrobials defined as HRA were identified from a previous time series analysis of relationship between antibiotic use and CDI rates in Ninewells Hospital. 15 In October 2008 the NHS Tayside policy for empirical treatment of infection changed to remove cefuroxime for any indication, include ceftriaxone only for meningitis, limit fluoroquinolones to a few specific indications and reduce use of clarithromycin, clindamycin and co-amoxiclav (Table S2) . Cefuroxime was also removed from the policy for antibiotic prophylaxis in general surgery (Table S3) .
The policy was implemented via provision of advice from clinical pharmacists at ward level supported by departmental presentations by the Chair of the Antimicrobial Management Group and Antimicrobial Pharmacist from October to December 2008 (Table S1 ).
Outcomes
Antimicrobial use data were obtained at ward level from the hospital pharmacy computer system and summarized as DDD per 1000 admissions per month, separately for Medicine and Surgery.
CDI data were obtained from the Infection Control Department and summarized as cases per 1000 admissions per month. The case definition was a patient with diarrhoea and toxin-positive stool, without toxin-positive stool in the previous 90 days. The laboratory diagnostic test changed 9 months post-intervention, but there were no changes to infection control policies over the study period (detailed in Table S1 ).
We measured 30 day mortality among all patients (deaths within 30 days of admission per 1000 admissions per month) and among patients who had a blood culture taken (deaths within 30 days of having a blood culture taken per 1000 patients with blood culture taken per month) as an indicator of sepsis mortality. 16 Patient-level hospital admissions and microbiology data were linked to the national register of deaths then anonymized by the Health Informatics Centre, University of Dundee. 17 Mortality was included as a balancing measure due to concerns from clinicians that a change in antimicrobial policy may result in inadequate treatment of patients with sepsis. We also examined postoperative acute kidney injury as a balancing measure, due to increased use of gentamicin as surgical prophylaxis in the new policy, and results are published elsewhere. 18 
Statistical analysis
We used segmented regression analysis of ITS data to estimate intervention effects, using lag terms to adjust models for autocorrelation present in residual terms and using heteroskedastic robust standard errors when residual terms were not homoskedastic. 19 Effect sizes are the estimated absolute and relative changes, with 95% CI, at 6 months (prescribing, mortality) or 12 months (CDI) post-intervention. Lower limits of 95% CI for estimated CDI rates that were negative were converted to zero. The absolute change is the difference between the modelled outcome at the specified post-intervention timepoint and the model estimate of the last pre-intervention data point and the relative change is the absolute change as a percentage of the model estimate of the last pre-intervention data point. All analyses were carried out in IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA).
Comparison with studies from systematic review
Of a total 241 studies in the Cochrane systematic review, eight planned ITS studies provided reliable prescribing and CDI data and had monthly or quarterly CDI rates for at least 12 months after the prescribing intervention. 5, [7] [8] [9] [10] [11] [12] [13] Six of these targeted HRA so were comparable to our intervention. 5, 8, 9, [11] [12] [13] The remaining two aimed to reduce use of all antibiotics. 7, 10 We made descriptive comparisons (setting, selection of HRA, etc.) between our study and the six comparable studies and reanalysed prescribing data from five, and CDI data from all six, studies using the same method described above to examine variation in effect (one study 11 did not present raw prescribing data to enable reanalysis). Pre-intervention CDI rates were converted to per 1000 OBD per month to enable comparison between studies. None of the six studies reported mortality. Owing to the heterogeneity of study design and outcome measures among the ITS studies, formal meta-analysis was not applicable. We also reanalysed data from the two studies targeting all antibiotics (not just HRA), but these were less directly comparable to our study.
Ethics
All patient-identifiable data were anonymized by the Health Informatics Centre (HIC) according to Standard Operating Procedures (SOP), which have been agreed with the NHS Tayside Caldicott Guardian and East of Scotland Research Ethics Committee. Studies using anonymized data and following HIC SOP do not need individual ethics review. All analyses were carried out in an ISO27001 and Scottish Government accredited data Safe Haven.
Results
HRA
In NHS Tayside use of HRA per 1000 admissions per month in the pre-intervention period varied, mainly from 4000 to 7000 DDD in Medicine versus 2000 to 4000 DDD in Surgery (Figure 1a and b) . In the pre-intervention period co-amoxiclav accounted for 36% of HRA in Medicine and Surgery. Other antimicrobial use, as a percentage of all HRA, in Medicine versus Surgery was: cephalosporin 5% versus 13%, clarithromycin 32% versus 6%, fluoroquinolone 19% versus 30% and clindamycin 6% versus 7% (further details available in Table S4 ).
The intervention was associated with progressive reductions in HRA in Medicine ( Figure 1a ) and Surgery (Figure 1b (Table 1) .
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CDI
In Medicine there was no significant pre-intervention trend in CDI rates, whereas in Surgery the rate was declining by 0.49 cases per 1000 admissions per month (CI 0.29-0.69) ( Table 1) . Immediately pre-intervention, there was a higher CDI rate in Medicine than Surgery at 22.0 versus 4.5 per 1000 admissions ( Table 1) .
The intervention was associated with a progressive decline in CDI rates in Medicine (Figure 1c ), but not in Surgery (Figure 1d ). At 12 months post-intervention CDI in Medicine reduced by 7.0 cases per 1000 admissions, although this was not quite statistically significant [relative change #24% (95% CI #55 to 6), Table 1 ]. In Surgery, there was no change associated with the intervention after 12 months (model estimate #0.1 CDI cases per 1000 admissions, relative change #2% (95% CI #116 to 112, Table 1 ), reflecting a levelling off from a downward pre-intervention trend ( Figure 1d ).
Mortality
All-cause 30 day mortality declined post-intervention in Medicine and Surgery (Figure 2a and b and Table S5 ), but there was no statistically significant association with the intervention, with relative reductions of 8% (95% CI #24 to 9) in Medicine and 2% (95% CI #35 to 31) in Surgery at 6 months post-intervention. Mortality in patients who had blood cultures taken also declined in both Medicine and Surgery (Figure 2c and d and Table S5 ), but again there were no statistically significant changes associated with the intervention, with relative changes of #14% (95% CI #39 to 11) and #12% (95% CI #46 to 23), respectively, at 6 months postintervention.
Comparable studies from systematic review
There were six studies targeting HRA with adequate (monthly or quarterly for at least 12 months) CDI data, 5, 8, 9, [11] [12] [13] one only included medicine for the elderly, 9 but others included all wards. Five were based in the UK, but the one US study included six intervention hospitals. 11 The definition of HRA varied considerably between studies and hospitals and CDI case definitions varied slightly. Not all studies reported diagnostic methods or infection control practices (Table 2 ).
All interventions were associated with statistically significant reduction in HRA use (Table 1 ). Changes at 6 months postintervention could not be estimated for one study, 11 but our High-risk antimicrobials and C. difficile JAC reanalysis of data from the remaining five estimated relative reductions of 27%-49%, were all statistically significant (Table 1) . Immediate pre-intervention CDI rates ranged from 0.6 to 2.7 cases per 1000 OBD per month across all eight settings (including in Ninewells Hospital) ( Table 2 ) and pre-intervention CDI rates were significantly reducing in three ( Table 1) . Reanalysis of CDI data from five of the six comparable studies estimated relative changes in CDI at 12 months post-intervention that were similar to the change in Medicine in Ninewells, but two had much wider CI: #40% (95% CI #124 to 43 8 ), #48% (95% CI #131 to 35 13 ). Reanalysis of CDI data from the remaining study 11 estimated much smaller relative changes, more similar to Surgery in Ninewells and with a similarly low immediate pre-intervention CDI rate [0.6 versus 0.8 per 1000 OBD per month (Table 2) ]. In only two of eight settings were estimated reductions in CDI at 12 months post-intervention statistically significant 9, 12 and both had relatively flat pre-intervention trends (although Price et al. 12 has a significant downward trend, the change per month is numerically very small meaning the slope is very shallow) ( Table 1) .
Studies targeting total antimicrobial use
Reanalysis of data from one of two studies targeting total antimicrobial use, set in an 861 bed tertiary care hospital, 7 
Discussion
In Ninewells Hospital, an intervention to reduce prescribing of antimicrobials associated with a high risk of CDI resulted in large and significant reductions in prescribing of targeted antimicrobials in both clinical settings evaluated. The estimated effects on CDI were inconsistent and influenced by pre-intervention rates and trends. Reanalysis of prescribing and CDI data from six similar previously published studies revealed similar large reductions in prescribing and inconsistent changes in CDI. In Ninewells Hospital, there was no evidence that the antimicrobial prescribing intervention was associated with any increase in 30 day mortality.
We analysed the effect of a real-world intervention in two clinical settings within our hospital using a statistically robust method for the analysis of quasi-experimental studies. The use of routine Lower limit of confidence limit was negative so adjusted to zero because a negative CDI rate is not possible.
e Courses " number of 7 day courses.
f Fixed effect coefficient and P value from segmented regression analysis in original publication; raw data were not available to allow reanalysis.
High-risk antimicrobials and C. difficile JAC data enabled complete case identification and complete antimicrobial dispensing data. In addition to examining the intended process (HRA prescribing) and outcome (CDI) measures, we also included mortality as a balancing measure, which no other similar studies did. A further strength was the reanalysis of published data from all similar interventions identified in a recent systematic review 4 using the same methods, allowing direct comparison of effect and helping to explain variation in effect size.
In some segmented regression analyses, the assumption is that pre-intervention trends would have continued throughout the study period in the absence of an intervention and the projection of the pre-intervention trend is used to estimate intervention effects. This can be problematic if the modelled projection breaches the limits of measurement, resulting in predicted negative incidence or proportions ,0% or .100%. Therefore, we projected the last pre-intervention timepoint forward, assuming a flat postintervention trend. In Surgery in Ninewells and one comparable study, 8 CDI rates were statistically significantly reducing preintervention and extrapolation of those trends would have breached 0 by 12 months post-intervention, with the result that the estimated intervention effect would inevitably have been an increase in CDI.
In all the analysed interventions there were significant reductions in the use of HRA, but there were only significant reductions in CDI in two (Table 1) . These results are in marked contrast to a previous systematic review, which concluded that antibiotic stewardship programmes were associated with a consistent, significant reduction in CDI (pooled risk ratio for CDI 0.48, 95% CI 0.38-0.62). 20 That analysis was based on 16 studies, only four of which 9,12,13,21 met inclusion criteria for the Cochrane systematic review. 4 One of those had ITS HRA prescribing data suitable for reanalysis but only aggregate CDI data so could not be included in this paper. 21 The other 12 studies were either uncontrolled before and after studies, which do not meet Cochrane criteria for inclusion in systematic reviews, 22 or ITS studies with methodological weaknesses. Analysing our Surgery data (Figure 1d ) as uncontrolled before and after gives a relative risk of CDI post-versus preintervention of 0.50 (95% CI 0.36-0.70), but this difference is clearly attributable to a steady decline in CDI in the preintervention period rather than an intervention effect (Figure 1d ). This highlights a difficulty in evaluating the impact of real-world antimicrobial stewardship interventions on downstream outcomes because there is often more than one prescribing intervention, healthcare professionals change behaviour before/without Patton et al.
an intervention and infection incidence is affected by outbreaks and infection control interventions.
In the eight settings we analysed, the pre-intervention CDI rates were lower for the two interventions with smaller estimated intervention effects from Ninewells Surgery and Ostrowsky et al., 11 and one with very wide confidence limits 8 (Table 2 ) and were already declining significantly in two of these, i.e. Ninewells Surgery and Dancer et al.
8 (Table 1 ). Declining CDI rates are likely multifactorial and, in addition to low baseline rates, make demonstrating an additional intervention effect very challenging. A Scottish study, more recent than those included in the systematic reviews above, used non-linear time series analysis to estimate associations between a change in antimicrobial prescribing policy and CDI rates, taking infection control interventions into account, and found that compared with predicted rates, CDI prevalence density in hospitals fell by 68% (mean reduction 1.01 per 1000 OBD, 0.27-1.76) following a change in antimicrobial policy. 23 Similarly emphasizing the importance of antimicrobial stewardship in the control of CDI, a recent study in England, using whole genome sequencing of C. difficile, demonstrated that declining CDI rates were largely explained by reductions in fluoroquinolone-resistant strains. 24 The decline in fluoroquinolone-resistant CDI was significantly associated with declining fluoroquinolone prescribing rates rather than infection control. 24 Both these approaches provide robust evaluations of the impact of stewardship on CDI, but the necessary data and analytical methods are not available for evaluation of most stewardship interventions.
The selection of targeted HRA could plausibly influence the effectiveness of prescribing interventions. Meta-analyses of casecontrol studies of patient-level CDI risk associated with specific antimicrobial exposure have varying results. In healthcare-associated CDI, exposure to cephalosporins, particularly third-generation (OR 3.20, 95% CI 1. ]. There were similarities in HRA selection across all eight settings we analysed (Table 2 ), but only the study of Ostrowsky et al.
11 included piperacillin/tazobactam and in that study cephalosporins were only targeted in two of six intervention sites and quinolones only in one (Table 1) . A recent ITS evaluation of multicentre antimicrobial stewardship in Australia, where targeted HRA were standardized across five hospitals, demonstrated an associated reduction in CDI despite low rates preintervention. 27 A recent review of country-level data on the use of different cephalosporins and CDI rates across Europe concludes that associations with CDI should be considered for individual Patton et al.
cephalosporin agents and argues that factors such as cumulative exposure are important, 3 which has been reported elsewhere. 28, 29 The use of certain cephalosporins in a controlled manner may be appropriate to maintain diversity and support long-term sustainable stewardship. 30 We measured mortality owing to concerns raised by clinicians that the change in antimicrobial policy could have led to undertreatment of patients with sepsis and we found no evidence of worse outcomes with the intervention. There was declining mortality throughout the study period (Figure 2 ). Our intervention was coincident with the start of the Scottish Patient Safety Programme 31 in 2008, which aimed to reduce hospital mortality through early recognition and management of deteriorating patients (although the Scottish Patient Safety Programme Sepsis Collaborative only began in 2012). A local sepsis improvement initiative in 2009 in Ninewells Hospital was associated with reduced time to first antibiotic dose in Medicine and Surgery, 16 but not mortality (C. A. Marwick and P. Davey, unpublished data), in a smaller study using manually collected patient data. There are limitations in using mortality as a stewardship outcome, due to confounding, but it does have value as a balancing measure and most studies do not report any clinical outcome data. 4 A very recent exception is a multicentre stewardship study, which reported reductions in infection-specific mortality and length of stay, in line with similar reductions in all patients, providing reassurance that the intervention did not worsen outcome. 27 This is consistent with our findings and supports the use of all-cause mortality as an outcome in broadly implemented interventions.
Targeted restriction of HRA is an important stewardship intervention, particularly when CDI rates are high and when hypervirulent strains of CDI are circulating within a population. Robust evaluation of the effect of real world stewardship interventions on outcomes other than prescribing remains methodologically challenging and worthy of further effort. 32 Pre-intervention outcome data should be examined before resource-intense interventions and evaluations are undertaken and all evaluations should include balancing measures. Although the included studies focused on restriction of HRA in relation to CDI, effective stewardship of all broad-spectrum antimicrobials is important to reduce adverse effects including healthcare-associated infection and the emergence of antimicrobial resistance.
